|
|
| Line 1: |
Line 1: |
| __NOTOC__
| | #REDIRECT [[Ticagrelor#Contraindications]] |
| {{Ticagrelor}}
| |
| {{CMG}}; {{AE}} {{JH}}
| |
| | |
| ==Contraindications==
| |
| | |
| ====History of Intracranial Hemorrhage====
| |
| | |
| BRILINTA is contraindicated in patients with a history of [[intracranial hemorrhage|intracranial hemorrhage (ICH)]] because of a high risk of recurrent [[ICH]] in this population ''[see [[Ticagrelor clinical studies|Clinical Studies]]]''.
| |
| | |
| ====Active Bleeding====
| |
| | |
| BRILINTA is contraindicated in patients with active pathological bleeding such as [[peptic ulcer]] or [[intracranial hemorrhage]] ''[see [[Ticagrelor warnings and precautions|Warnings and Precautions]] and [[Ticagrelor adverse reactions|Adverse Reactions]]]''.
| |
| | |
| ====Severe Hepatic Impairment====
| |
| | |
| BRILINTA is contraindicated in patients with severe [[hepatic impairment]] because of a probable increase in exposure, and it has not been studied in these patients. Severe [[hepatic impairment]] increases the risk of bleeding because of reduced synthesis of [[coagulation]] proteins ''[see [[Ticagrelor clinical pharmacology|Clinical Pharmacology]]]''.
| |
| | |
| ====Hypersensitivity====
| |
| | |
| BRILINTA is contraindicated in patients with [[hypersensitivity]] (e.g. [[angioedema]]) to ticagrelor or any component of the product [see [[Ticagrelor adverse reactions|Adverse Reactions]]]''.<ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = BRILINTA (TICAGRELOR) TABLET [ASTRAZENECA LP] | url = http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=f7b3f443-e83d-4bf2-0e96-023448fed9a8 | publisher = | date = | accessdate = }}</ref>
| |
| | |
| ==References==
| |
| | |
| {{Reflist}}
| |
| | |
| [[Category:ADP receptor inhibitors]]
| |
| [[Category:Cardiovascular Drugs]]
| |
| [[Category:Drugs]]
| |